Gene therapy has begun to show promise as a potential therapeutic approaches, with licensed treatments already available for lipoprotein lipase deficiency and haemophilia A.

The Myrovlytis Trust supports investigations into renal gene therapies, which may also have application in a range of genetic kidney disorders.

Learn more about two of our recent projects:

Dr Richard Harbottle: Using non-viral S/MAR plasmid vectors to develop prophylactic gene therapy for Birt-Hogg-Dube Syndrome

Dr Justin Roth: Development of virus- and cell-based targeting platforms for renal gene therapy